Bio-Works secures another order from PolyPeptide

Press release October 23, 2018

Bio-Works has received an order of 1,6 million SEK from PolyPeptide. In total, Bio-Works has received seven orders from PolyPeptide, four during 2017 and three during 2018. PolyPeptide is one of the largest contract manufacturers in the world for peptide pharmaceuticals. They control 25 % of the global market for contract manufacturing of peptide pharmaceuticals. This latest order will be delivered during the first quarter of 2019.

Mats Johnson, Bio-Works CEO:

”We are happy that PolyPeptide uses Bio-Works’ products for optimal production efficiency. The high frequency of orders from PolyPeptide shows the trust they have for our products. We look forward to a continued good collaboration.”

Bio-Works has seen a clear increase in recurring orders from both existing and new customers. The order values are also increasing and the customer base is growing. Of the 203 customers Bio-Works has presently, 45 projects are in scale-up and four in production phase. We expect that several of our customers’ scale-up projects will move into production in the coming months. In industrial production each project a customer is running can be worth up to 10 million SEK in yearly revenue for Bio-Works.

For more information please visit Bio-Works’ homepage, www.bio-works,com, or contact Mats Johnson, CEO for Bio-Works, e-mail: mats.johnson@bio-works.com, telephone: +46 70 516 53 37.

About Bio-Works

Bio-Works designs, develops, manufactures and supplies innovative leading edge agarose products for chromatographic separation of proteins, peptides and other biomolecules. The company is staffed by people with long experience in the biotech industry and particularly with protein separation media. Bio-Works’ agarose-based high performance products are used for purification in the life science research phase as well as the commercial production of biopharmaceuticals and diagnostic products in large scale. The products are sold globally through our own organization and via distributors. Bio-Works facilities are located in the Uppsala Business Park Uppsala, Sweden. Company processes and a Quality Management System follow the standards of ISO 9001:2008. The Bio-Works’ share is traded on Nasdaq First North in Stockholm. FNCA Sweden AB is the Certified Adviser.

Bio-Works launches WorkBeads affimAb for purification of tomorrow’s biological pharmaceuticals

Press release October 9, 2018

Bio-Works today announces the launch of WorkBeads affimAb for purification of new biological pharmaceuticals on a large scale. As for all Bio-Works’ products, focus is on improved production efficiency. We aim to capture the target molecule (the pharmaceutical product) in the shortest possible time and to achieve a purification process that is as efficient as possible. WorkBeads affimAb has unique features that provide great value for our customers.

Almost half of today’s biological pharmaceuticals are monoclonal antibodies. They are purified in a process including several steps, one of which is to use chromatography media where Protein A is coupled to the resin in order to to capture the monoclonal antibody. Many new biological pharmaceuticals are under development and new biosimilars (biological copies of biopharmaceuticals) are being developed at a rapidly increasing pace. This happens all over the world, not least in Asia. This faster pace of development leads to an increased demand for Protein A-based media, from established and new producers of pharmaceutical products, with a focus on attractive pricing in relation to production efficiency.

The market for Protein A-based chromatography media is worth more than 4 billion SEK and is growing by more than 8 % per year. The market is dominated by one company and one product. The dynamics of the business are such that the pharmaceutical producers are actively looking for new suppliers as alternatives to the market leader.

WorkBeads affimAb is built on Bio-Works patented agarose technology. Our Korean partner Amicogen’s unique Protein A is coupled to our unique resin as base. Bio-Works has, in comparison with relevant competing products, higher dynamic binding capacity (so called DBC) at high flow rates and very high stability for the necessary cleaning between process cycles. Thus, WorkBeads affimAb is in many key production parameters superior to the market leader’s product in terms of amount of target molecule bound (ca. 30 % more at high flow rate), but also expected lifetime in the customer’s application.

Mats Johnson, Bio-Works CEO:

”We are very satisfied that we have in such a short time been able to combine our technology base with Amicogen’s variant of Protein A to create a fantastic product for which there is a large need in the market. This product opens an important new market segment for us. We see this as a first step in our collaboration with Amicogen. Bio-Works is planning to continue to develop new products based on both companies’ unique technology bases. We continue step-by-step to build the company according to our plan.”

For more information please visit Bio-Works’ homepage, www.bio-works.com, or contact Mats Johnson, CEO for Bio-Works, e-mail: mats.johnson@bio-works.com, telephone: +46 70 516 53 37.

About Bio-Works

Bio-Works designs, develops, manufactures and supplies innovative leading edge agarose products for chromatographic separation of proteins, peptides and other biomolecules. The company is staffed by people with long experience in the biotech industry and particularly with protein separation media. Bio-Works’ agarose-based high performance products are used for purification in the life science research phase as well as the commercial production of biopharmaceuticals and diagnostic products in large scale. The products are sold globally through our own organization and via distributors. Bio-Works facilities are located in the Uppsala Business Park Uppsala, Sweden. Company processes and a Quality Management System follow the standards of ISO 9001:2008. The Bio-Works’ share is traded on Nasdaq First North in Stockholm. FNCA Sweden AB is the Certified Adviser.

Bio-Works increases target for the number of new customers 2018

Press release October 8, 2018

After the third quarter of 2018, Bio-Works has 203 customers, which means that 27 new customers have been added during the third quarter. The number of customers working with scale-up has increased by five and in total we now have 45 customers in scale-up after the third quarter 2018. This means that we have passed our target for 2018 (to grow the customer base with 75 % to a total of 184 customers ) with a good margin. We will therefore increase our target for this year to 235 customers which would mean an increase of the customer base to 124 %.

Our sales process follows the fact that our industrial customers initially work at lab scale and then start to scale-up their processes for purification of the target molecules (future products). In the scale-up phase our customers start to buy larger quantities of our products. This is a process which takes 2-5 years depending on the particular customer project. Bio-Works’ strategy is therefore to start at lab scale and then support the customers through process development to production scale. When the customers’ production process is optimized and their products reach the market, we achieve a lock-in effect for our products and the customer has a major hurdle to overcome if they are to change supplier. This lock-in effect, which is advantageous for Bio-Works, is particularly significant when it comes to biological pharmaceuticals due to the regulatory requirements.

It is therefore important for Bio-Works to increase our pipeline of new customers with greatest possible urgency. Bio-Works follows the customers in their projects and when the customers scale-up their processes we join them in their success, with a subsequent stable, long-term earnings potential.

Mats Johnson, Bio-Works CEO:
”We have rapidly received a good response in our focus on the biopharmaceutical and diagnostics industry which we can see in the number of new customers and in new customers with scale-up projects. Our strengthened sales organization in Europe is now fully up-and-running and our initial sales effort in North America is beginning to result in new customers and in new scale-up customers. Also in Asia we can now see a good growth of customers in lab scale as well as customers with scale-up projects.”

For more information please visit Bio-Works’ homepage, www.bio-works.com, or contact Mats Johnson, CEO for Bio-Works, e-mail: mats.johnson@bio-works.com, telephone: +46 70 516 53 37.

About Bio-Works

Bio-Works designs, develops, manufactures and supplies innovative leading edge agarose products for chromatographic separation of proteins, peptides and other biomolecules. The company is staffed by people with long experience in the biotech industry and particularly with protein separation media.  Bio-Works’ agarose based high performance products are used for purificationin the life science  research phase as well as the commercial production of biopharmaceuticals and diagnostic products in large scale. The products are sold globally with our own organization and via distributors. Bio-Works facilities are located in the Uppsala Business Park Uppsala, Sweden. Company processes and a Quality Management System follows the standards of ISO 9001:2008. The Bio-Works’ share is traded on Nasdaq First North in Stockholm. FNCA Sweden AB is the Certified Adviser.

Bio-Works separation media, WorkBeads™, is being used for full scale production of an FDA approved biopharmaceutical

Press release April 12, 2018

Bio-Works’ separation media, WorkBeads, has become standard for the production of an FDA approved biopharmaceutical which is being used globally for treatment of patients. This pharmaceutical is the first of several ongoing pharmaceutical projects, where WorkBeads is being used, which has come all the way from lab scale to full scale production.

Bio-Works experiences a clear trend where an increasing number of the customers place re-occurring WorkBeads orders. The trend indicates that many of Bio-Works’ customers are moving closer to full scale production. The regulatory authorities often demand that the same separations media is used in production scale as has been used during the late clinical stage (phase 3). This means repeated orders and continuous revenue for Bio-Works during the life time of the pharmaceutical product.

Mats Johnson, Bio-Works CEO:
”We have for a long time worked intensively to commercialize WorkBeads. The fact that WorkBeads now is used for production of an FDA approved pharmaceutical is a breakthrough and a significant proof of confidence which will further strengthen the trust in our products. It decreases the threshold for the use of Bio-Works’ products in new projects. Going forward this breakthrough will lead to increased revenue for Bio-Works and to new sales opportunities.”

For more information please visit Bio-Works’ homepage, www.bio-works.com, or contact Mats Johnson, CEO for Bio-Works, e-mail: mats.johnson@bio-works.com, telephone: +46 70 516 53 37.

About Bio-Works

Bio-Works designs, develops, manufactures and supplies innovative leading edge agarose products for chromatographic separation of proteins, peptides and other biomolecules. The company is staffed by people with long experience in the biotech industry and particularly with protein separation media.  Bio-Works’ agarose based high performance products are used for purificationin the life science  research phase as well as the commercial production of biopharmaceuticals and diagnostic products in large scale. The products are sold globally with our own organization and via distributors. Bio-Works facilities are located in the Uppsala Business Park Uppsala, Sweden. Company processes and a Quality Management System follows the standards of ISO 9001:2008. The Bio-Works’ share is traded on Nasdaq First North in Stockholm. FNCA Sweden AB is the Certified Adviser.